Evidence map›Paper›PMID 27104803›Full record

Trial reportJournal of affective disorders2016

Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.

Jeffrey R Vittengl, Lee Anna Clark, Michael E Thase, Robin B Jarrett

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of affective disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Jeffrey R VittenglDepartment of Psychology, Truman State University, United States. Electronic address: vittengl@truman.edu.
Lee Anna ClarkDepartment of Psychology, University of Notre Dame, United States.
Michael E ThaseDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, United States.
Robin B JarrettDepartment of Psychiatry, The University of Texas Southwestern Medical Center, United States. Electronic address: Robin.Jarrett@UTSouthwestern.edu.
The University of Texas Southwestern Medical Center · USTruman State University · USUniversity of Notre Dame · USUniversity of Pennsylvania · US

Funding

PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONR01MH058397 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2000 to 2011
$4.1M
PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONR01MH058356 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THASE, MICHAEL E · 2000 to 2010
$3.5M
Are Cognitive Therapy's Antidepressant Effects Durable?R01MH069619 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2004 to 2009
$1.7M
Are Cognitive Therapy's Antidepressant Effects Durable?R01MH069618 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRIEDMAN, EDWARD S. · 2004 to 2008
$1.5M
Cognitive Therapy for High Risk &Refractory DepressionK24MH001571 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2005 to 2009
$625k
NIMH NIH HHS K24 MH001571NIMH NIH HHS R01 MH058356NIMH NIH HHS R01 MH058397NIMH NIH HHS R01 MH069618NIMH NIH HHS R01 MH069619
6 · The paper itself

Abstract

backgroundSocial-interpersonal dysfunction increases disability in major depressive disorder (MDD). Here we clarified the durability of improvements in social-interpersonal functioning made during acute-phase cognitive therapy (CT), whether continuation CT (C-CT) or fluoxetine (FLX) further improved functioning, and relations of functioning with depressive symptoms and relapse/recurrence.

methodAdult outpatients (N=241) with recurrent MDD who responded to acute-phase CT with higher risk of relapse (due to unstable or partial remission) were randomized to 8 months of C-CT, FLX, or pill placebo plus clinical management (PBO) and followed 24 additional months. We analyzed repeated measures of patients' social adjustment, interpersonal problems, dyadic adjustment, depressive symptoms, and major depressive relapse/recurrence.

resultsLarge improvements in social-interpersonal functioning occurring during acute-phase CT (median d=1.4) were maintained, with many patients (median=66%) scoring in normal ranges for 32 months. Social-interpersonal functioning did not differ significantly among C-CT, FLX, and PBO arms. Beyond concurrently measured residual symptoms, deterioration in social-interpersonal functioning preceded and predicted upticks in depressive symptoms and major depressive relapse/recurrence. LIMITATIONS: Results may not generalize to other patient populations, treatment protocols, or measures of social-interpersonal functioning. Mechanisms of risk connecting poorer social-interpersonal functioning with depression were not studied.

conclusionsAverage improvements in social-interpersonal functioning among higher-risk responders to acute phase CT are durable for 32 months. After acute-phase CT, C-CT or FLX may not further improve social-interpersonal functioning. Among acute-phase CT responders, deteriorating social-interpersonal functioning provides a clear, measurable signal of risk for impending major depressive relapse/recurrence and opportunity for preemptive intervention.

Indexed as

Social AdjustmentAdultCognitive Behavioral TherapyFemaleFluoxetineFollow-Up StudiesHumansMajor Depressive DisorderMaleMiddle AgedOutcome Assessment, Health CareRecurrenceSecondary PreventionSelective Serotonin Reuptake InhibitorsFluoxetineSelective Serotonin Reuptake InhibitorsCognitive therapyContinuation treatmentRelapseResidual symptomsSocial-interpersonal functioning

Identifiers

PMID27104803
PMCPMC4862892
OpenAlexW2336189935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.